Assessing the bioequivalence of biosimilars: The Retacrit® case
- 31 May 2009
- journal article
- research article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 14 (9-10), 495-499
- https://doi.org/10.1016/j.drudis.2009.02.003
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- The First Biosimilar EpoetinClinical Journal of the American Society of Nephrology, 2008
- Immunologic mechanisms of EPO-associated pure red cell aplasiaBest Practice & Research Clinical Haematology, 2005
- Factors influencing the immunogenicity of therapeutic proteinsNephrology Dialysis Transplantation, 2005
- Epoetin-Induced Autoimmune Pure Red Cell AplasiaJournal of the American Society of Nephrology, 2005
- Characterizing biological products and assessing comparability following manufacturing changesNature Biotechnology, 2004